Generic

Empagliflozin 25mg + Linagliptin 5mg

Description

Emjenta 25/5 is a combination oral anti-diabetic medication containing Empagliflozin (25mg) and Linagliptin (5mg). It improves glycemic control in adults with type 2 diabetes mellitus (T2DM). The dual mechanism helps lower blood glucose levels by increasing urinary glucose excretion and enhancing insulin secretion.

Benefits

Emjenta 25/5 is highly effective in managing type 2 diabetes by offering dual benefits—reducing blood sugar through the kidneys (Empagliflozin) and stimulating insulin secretion (Linagliptin). It helps in weight reduction, blood pressure control, and reducing the risk of cardiovascular events in diabetic patients.

Ingredients

Each tablet contains:

• Empagliflozin 25mg: An SGLT2 inhibitor that promotes glucose excretion through urine.
• Linagliptin 5mg: A DPP-4 inhibitor that increases insulin release and decreases glucagon secretion.

Uses and Doses

Emjenta 25/5 is used to control blood sugar levels in type 2 diabetes patients who require a combination of SGLT2 and DPP-4 inhibitors.

• Recommended dose: One tablet daily, taken orally with or without food.
• For renal impairment: No dose adjustment is required.
• No clinical dose adjustment is recommended for hepatic impairment, but caution should be taken.
• For elderly patients: No adjustment is needed, but limited data is available for patients over 80.

Side Effects

Common side effects include hypoglycemia, urinary tract infections, genital fungal infections, dehydration, and increased LDL cholesterol. Some patients may experience pancreatitis or allergic reactions.

How to Use

Take one tablet daily, preferably at the same time every day. Swallow whole with water. Do not split, crush, or chew. If a dose is missed, take it as soon as remembered, but do not double it.

Pregnancy & Lactation

Emjenta 25/5 should be avoided during pregnancy and breastfeeding, as its safety is not well established. If necessary, alternative diabetes management should be considered.

Precautions and Warnings

Patients should monitor kidney function regularly. Dehydration and hypotension may occur, especially in elderly patients or those using diuretics. Hypoglycemia risk increases when used with insulin or sulfonylureas. Monitor for genital infections and urinary tract infections.

Safety Information

Do not use if allergic to Empagliflozin or Linagliptin. Avoid alcohol consumption as it may worsen side effects. Regular monitoring of blood sugar and kidney function is required.

Indications

Emjenta 25/5 is indicated for:

• Management of type 2 diabetes mellitus
• Combination therapy when metformin alone is insufficient
• Weight and cardiovascular risk reduction in diabetic patients

Pharmacology

Empagliflozin works by inhibiting SGLT2, reducing glucose reabsorption in the kidneys, and increasing urinary glucose excretion. Linagliptin blocks DPP-4, increasing incretin hormones that stimulate insulin release and lower glucagon secretion, improving glucose metabolism.

Therapeutic Class

Oral anti-diabetic drugs (SGLT2 inhibitors & DPP-4 inhibitors)

Storage Conditions

Store below 30°C, away from moisture and direct sunlight. Keep out of reach of children.

3 FAQ

1. Can Emjenta 25/5 cause weight loss?
Yes, Empagliflozin promotes weight loss by increasing urinary glucose excretion.

2. Can Emjenta 25/5 be used alone?
No, it is used when diet, exercise, and other diabetes medications are insufficient.

3. Does Emjenta 25/5 cause dehydration?
Yes, it may increase urine output, leading to dehydration and low blood pressure, especially in elderly patients.

Disclaimer

This information is for educational purposes only. Consult a doctor before using Emjenta 25/5, especially if you have kidney disease, heart conditions, or take other medications.

Keywords: Emjenta 25/5, Empagliflozin Linagliptin, type 2 diabetes medication, diabetes control, blood sugar management, SGLT2 inhibitor, DPP-4 inhibitor, glucose excretion, kidney function, hypoglycemia prevention, diabetic care, oral anti-diabetic drugs, diabetic weight loss, urine glucose excretion, cardiovascular diabetes treatment, diabetes combination therapy, sugar control pills, advanced diabetes treatment, prescription diabetes medication, NIPRO JMI Pharma.